Tags

Type your tag names separated by a space and hit enter

Hepatitis E virus.
Med Mal Infect. 2013 Jul; 43(7):263-70.MM

Abstract

Hepatitis E virus (HEV) is responsible for major outbreaks of acute hepatitis in developing countries where it was first described as a waterborne disease, transmitted by drinking water contaminated with feces. Attention was focused on HEV in developed countries and its associated diseases in recent years as a result of increasing reports of autochthonous infections. Hepatitis E is the zoonotic cause of these acute infections, and mainly in men over 50 years of age. The clinical manifestations and laboratory abnormalities of hepatitis E infections in immunocompetent patients cannot be distinguished from those caused by other hepatitis viruses. HEV is a major public health concern in immunocompromised patients because their infections can become chronic. The specific etiology of cases of hepatitis E infection can be diagnosed by serological testing and detecting viral RNA. Ribavirin is currently the reference treatment for HEV infections in immunocompromised patients. Several vaccines have proved safe and effective in clinical trials, but none have been approved for use in Europe yet.

Authors+Show Affiliations

Inserm, U563, centre de physiopathologie de Toulouse Purpan, 31300 Toulouse, France. abravanel.f@chu-toulouse.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23608595

Citation

Abravanel, F, et al. "Hepatitis E Virus." Medecine Et Maladies Infectieuses, vol. 43, no. 7, 2013, pp. 263-70.
Abravanel F, Lhomme S, Dubois M, et al. Hepatitis E virus. Med Mal Infect. 2013;43(7):263-70.
Abravanel, F., Lhomme, S., Dubois, M., Peron, J. M., Alric, L., Kamar, N., & Izopet, J. (2013). Hepatitis E virus. Medecine Et Maladies Infectieuses, 43(7), 263-70. https://doi.org/10.1016/j.medmal.2013.03.005
Abravanel F, et al. Hepatitis E Virus. Med Mal Infect. 2013;43(7):263-70. PubMed PMID: 23608595.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hepatitis E virus. AU - Abravanel,F, AU - Lhomme,S, AU - Dubois,M, AU - Peron,J-M, AU - Alric,L, AU - Kamar,N, AU - Izopet,J, Y1 - 2013/04/20/ PY - 2013/03/02/received PY - 2013/03/12/revised PY - 2013/03/12/accepted PY - 2013/4/24/entrez PY - 2013/4/24/pubmed PY - 2014/3/25/medline KW - Chronic infection KW - Hepatitis E virus KW - Infection chronique KW - Virus de l’hépatite E SP - 263 EP - 70 JF - Medecine et maladies infectieuses JO - Med Mal Infect VL - 43 IS - 7 N2 - Hepatitis E virus (HEV) is responsible for major outbreaks of acute hepatitis in developing countries where it was first described as a waterborne disease, transmitted by drinking water contaminated with feces. Attention was focused on HEV in developed countries and its associated diseases in recent years as a result of increasing reports of autochthonous infections. Hepatitis E is the zoonotic cause of these acute infections, and mainly in men over 50 years of age. The clinical manifestations and laboratory abnormalities of hepatitis E infections in immunocompetent patients cannot be distinguished from those caused by other hepatitis viruses. HEV is a major public health concern in immunocompromised patients because their infections can become chronic. The specific etiology of cases of hepatitis E infection can be diagnosed by serological testing and detecting viral RNA. Ribavirin is currently the reference treatment for HEV infections in immunocompromised patients. Several vaccines have proved safe and effective in clinical trials, but none have been approved for use in Europe yet. SN - 1769-6690 UR - https://www.unboundmedicine.com/medline/citation/23608595/Hepatitis_E_virus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0399-077X(13)00074-7 DB - PRIME DP - Unbound Medicine ER -